Julien Lazarovici

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont et al. · The Lancet Haematology · 2018 · 292 citations

Pharmacy, Hematology, Immunology +16

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma

Charles Herbaux, Jordan Gauthier, Pauline Brice et al. · Blood · 2017 · 216 citations

Life Sciences, Immunology, Oncology +11

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Olivier Casasnovas, Réda Bouabdallah, Pauline Brice et al. · The Lancet Oncology · 2019 · 209 citations · Full text

Medicine, Oncology, Radiation Oncology +8

Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Catherine Thiéblemont, Hervé Tilly, María Gomes da Silva et al. · Journal of Clinical Oncology · 2017 · 195 citations

Medicine, Oncology, Pharmacotherapy +14

Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers

Cédric Rossi, Julia Gilhodes, Marie Maerevoet et al. · American Journal of Hematology · 2018 · 122 citations · Full text

Medicine, Oncology, Pharmacotherapy +17